A detailed history of Two Sigma Investments, LP transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 1,402,075 shares of HRTX stock, worth $1.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,402,075
Previous 1,106,436 26.72%
Holding current value
$1.5 Million
Previous $3.87 Million 27.94%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.73 - $3.67 $511,455 - $1.08 Million
295,639 Added 26.72%
1,402,075 $2.79 Million
Q2 2024

Aug 14, 2024

BUY
$2.32 - $3.86 $2.38 Million - $3.96 Million
1,025,872 Added 1273.36%
1,106,436 $3.87 Million
Q1 2024

May 15, 2024

BUY
$1.71 - $3.06 $137,764 - $246,525
80,564 New
80,564 $223,000
Q2 2023

Aug 14, 2023

SELL
$1.11 - $2.88 $124,320 - $322,560
-112,000 Reduced 75.42%
36,500 $42,000
Q1 2023

May 15, 2023

SELL
$1.51 - $3.25 $188,117 - $404,888
-124,581 Reduced 45.62%
148,500 $224,000
Q4 2022

Feb 14, 2023

BUY
$2.25 - $4.67 $271,941 - $564,430
120,863 Added 79.4%
273,081 $682,000
Q3 2022

Nov 14, 2022

BUY
$2.66 - $5.37 $120,133 - $242,525
45,163 Added 42.19%
152,218 $642,000
Q2 2022

Aug 15, 2022

BUY
$2.3 - $6.29 $246,226 - $673,375
107,055 New
107,055 $299,000
Q2 2020

Aug 14, 2020

SELL
$10.89 - $21.47 $1.27 Million - $2.5 Million
-116,226 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$10.23 - $24.56 $181,654 - $436,111
-17,757 Reduced 13.25%
116,226 $1.36 Million
Q4 2019

Feb 14, 2020

BUY
$17.42 - $26.61 $2.33 Million - $3.57 Million
133,983 New
133,983 $3.15 Million
Q3 2018

Nov 14, 2018

SELL
$30.0 - $40.85 $263,400 - $358,663
-8,780 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$26.4 - $42.0 $231,792 - $368,760
8,780 New
8,780 $341,000

Others Institutions Holding HRTX

About HERON THERAPEUTICS, INC.


  • Ticker HRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,774,000
  • Market Cap $127M
  • Description
  • Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...
More about HRTX
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.